0.85EUR
42.09 MEUR
174.25 MEUR
19.32 M
About SHIN NIPPON BIOMED.LAB.
Sector
CEO
Ryoichi Nagata
Website
Headquarters
Tokyo
Employees (FY)
1.21 K
Founded
1957
ISIN
JP3379950003
FIGI
BBG000BSTF82
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells. The Clinical Business segment provides the support services for clinical trials and related statistical, analytical, and consulting services for all aspects of new drug development. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SHIN NIPPON BIOMED.LAB. stocks are traded under the ticker YB3.
SHIN NIPPON BIOMED.LAB. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for SHIN NIPPON BIOMED.LAB. has a max estimate of 21.40 EUR and a min estimate of 17.10 EUR.
YB3 earnings for the last quarter are 0.24 EUR per share, whereas the estimation was 0.17 EUR resulting in a 41.86% surprise. The estimated earnings for the next quarter are 0.26 EUR per share. See more details about SHIN NIPPON BIOMED.LAB. earnings.
SHIN NIPPON BIOMED.LAB. revenue for the last quarter amounts to 38.49 M EUR despite the estimated figure of 42.06 M EUR. In the next quarter revenue is expected to reach 53.00 M EUR.
Yes, you can track SHIN NIPPON BIOMED.LAB. financials in yearly and quarterly reports right on TradingView.
YB3 net income for the last quarter is 5.32 M EUR, while the quarter before that showed 10.08 M EUR of net income which accounts for −47.25% change. Track more SHIN NIPPON BIOMED.LAB. financial stats to get the full picture.
SHIN NIPPON BIOMED.LAB. dividend yield was 1.82% in 2022, and payout ratio reached 34.35%. The year before the numbers were 2.36% and 23.36% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, YB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHIN NIPPON BIOMED.LAB. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 1.21 K employees. See our rating of the largest employees — is SHIN NIPPON BIOMED.LAB. on this list?
We've gathered analysts' opinions on SHIN NIPPON BIOMED.LAB. future price: according to them, YB3 price has a max estimate of 21.38 EUR and a min estimate of 17.11 EUR. Read a more detailed SHIN NIPPON BIOMED.LAB. forecast: see what analysts think of SHIN NIPPON BIOMED.LAB. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHIN NIPPON BIOMED.LAB. EBITDA is 37.13 M EUR, and current EBITDA margin is 27.28%. See more stats in SHIN NIPPON BIOMED.LAB. financial statements.